Loading
MSH3 (DNA mismatch repair protein Msh3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Colorectal cancer.
Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerises with MSH2 to form MutS beta which binds to DNA mismatches thereby initiating DNA repair. When bound, the MutS beta heterodimer bends the DNA helix and shields approximately 20 base pairs.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming 7-Ethyl-10-Hydroxycamptothecin and Oxaliplatin. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes genetic literature 0.49, affected pathway 0.61, literature 0.93, genetic association 0.92, somatic mutation 0.58, animal model 0.45).
In plain words · MSH3 (DNA mismatch repair protein Msh3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Colorectal cancer.
MSH3 (DNA mismatch repair protein Msh3) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer and Colorectal cancer.
Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerises with MSH2 to form MutS beta which binds to DNA mismatches thereby initiating DNA repair.
No product in this corpus aims at MSH3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Germline variant: UniProt lists Endometrial cancer (ENDMC) under involvement in disease, and the record is a DNA repair gene; the medicines linked to it act through the loss (synthetic lethality) or use the variant to pick patients. HPA MSH3: RNA low tissue specificity; no normal tissue stained high. Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Endometrial cancer, Colorectal cancer); Open Targets associates it with 3 specific cancer types at or above 0.5 (familial adenomatous polyposis 4, endometrial carcinoma, hereditary neoplastic syndrome). (Rule 2 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P20585; Human Protein Atlas MSH3 tissue; Open Targets ENSG00000113318 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Fujii et al, J. Biol. Chem, 1989, "Isolation and characterization of cDNA clones derived from the divergently transcribed gene in the region upstream from the human dihydrofolate reductase gene". Source.
Sources: HGNC HGNC:7326 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P20585 (protein name, function text, keywords and locations (REST API)); CIViC gene MSH3 (1 evidence items, 0 assertions, 1 variants; diseases: Colon Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000113318 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: endometrial cancer 0.69 (GraphQL API, CC0))
Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerises with MSH2 to form MutS beta which binds to DNA mismatches thereby initiating DNA repair. When bound, the MutS beta heterodimer bends the DNA helix and shields approximately 20 base pairs. MutS beta recognises large insertion-deletion loops (IDL) up to 13 nucleotides long. After mismatch binding, forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. Locus 5q14.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MSH3" OR ABSTRACT:"MSH3" OR TITLE:"mutS homolog 3" OR ABSTRACT:"mutS homolog 3" OR TITLE:"DNA mismatch repair protein Msh3" OR ABSTRACT:"DNA mismatch repair protein Msh3" OR TITLE:"MRP1" OR ABSTRACT:"MRP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MSH3, not a curated reading list.